Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 89 of 151

  1. NBI-1117570-SCZ2035

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 2 small molecule active

    1 trial

  2. NBI-5788

    NEUROCRINE BIOSCIENCES INC

    Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  3. NBI-74788

    NEUROCRINE BIOSCIENCES INC

    CAH - Congenital Adrenal Hyperplasia

    phase 2 small molecule completed

    1 trial

  4. NBI-74788

    NEUROCRINE BIOSCIENCES INC

    Congenital adrenal hyperplasia (CAH)

    phase 2 small molecule active

    1 trial

  5. NBI-827104

    NEUROCRINE BIOSCIENCES INC

    Epileptic Encephalopathy

    phase 2 small molecule terminated

    2 trials

  6. NBI-827104

    NEUROCRINE BIOSCIENCES INC

    Essential Tremor

    phase 2 small molecule completed

    1 trial

  7. NBI-921352

    NEUROCRINE BIOSCIENCES INC

    Focal Onset Seizure

    phase 2 small molecule completed

    2 trials

  8. NBI-921352

    NEUROCRINE BIOSCIENCES INC

    SCN8A Developmental and Epileptic Encephalopathy Syndrome

    phase 2 small molecule active

    2 trials

  9. NBI-98854

    NEUROCRINE BIOSCIENCES INC

    Tourette Syndrome

    phase 2 small molecule terminated

    4 trials

  10. NBP Softgel Capsules

    NovaBridge Biosciences

    AIS

    phase 2 small molecule completed

    1 trial

  11. NBS10

    LISATA THERAPEUTICS, INC.

    ST Segment Elevation Myocardial Infarction

    phase 2 mab completed

    1 trial

  12. NDI-034858

    Takeda

    Psoriatic Arthritis

    phase 2 small molecule completed

    1 trial

  13. NDI-034858 study drug

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  14. NDV01 intravesical controlled release formulation of gemcitabine and docetaxel

    RELMADA THERAPEUTICS, INC.

    Non Muscle Invasive Bladder Cancer

    phase 2 small molecule active

    1 trial

  15. NEO-201 in combination with pembrolizumab

    Chongqing Precision Biotech Co., Ltd

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. NEO-TIM

    Fondazione Telethon ETS

    high-risk, surgically resectable BRAF mutated and wild-type Melanoma

    phase 2 small molecule active

    1 trial

  17. NERATINIB

    PUMA BIOTECHNOLOGY, INC.

    Stage IV (Metastatic) Breast Cancer

    phase 2 small molecule terminated

    1 trial

  18. NERATINIB, Sindiar 2 mg cápsulas duras

    Ningbo Cancer Hospital

    HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Breast Cancer.

    phase 2 small molecule active

    1 trial

  19. NET-MS

    Fondazione Telethon ETS

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  20. NGF-CP-201

    Dompe' Farmaceutici S.p.A.

    Spastic Cerebral Palsy

    phase 2 small molecule active

    1 trial

  21. NGF0123

    Dompe' Farmaceutici S.p.A.

    Dry Eye

    phase 2 small molecule active

    1 trial

  22. NIBIT-ML-1

    Fondazione Telethon ETS

    MM and NSCLC patients resistant to anti-PD-1/PD-L1 therapy

    phase 2 small molecule active

    1 trial

  23. NIVOLUMAB

    Disc Medicine

    Peritoneal Mesothelioma

    phase 2 small molecule active

    1 trial

  24. NIVOLUMAB, BT5528

    BICYCLE THERAPEUTICS

    Advanced Malignancies Associated with EphA2 Expression

    phase 2 small molecule active

    1 trial

  25. NIVOLUMAB, TEDOPI

    Fondazione Telethon ETS

    metastatic non-small-cell lung cancer

    phase 2 small molecule active

    1 trial

  26. NJMU-BC01

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  27. NK cell and PD-1 antibody

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 other completed

    1 trial

  28. NK cell perfusion group

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Abortion, Missed

    phase 2 mab active

    1 trial

  29. NK cells

    Hospital Authority, Hong Kong

    Hepatocellular Carcinoma

    phase 2 mab active

    1 trial

  30. NK cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 2 mab active

    1 trial

  31. NKTR-102

    Nektar Therapeutics UK Limited

    Tumor

    phase 2 small molecule completed

    1 trial

  32. NKTR-102

    Nektar Therapeutics UK Limited

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  33. NKTR-102 100 mg/m2

    Nektar Therapeutics UK Limited

    Tumor

    phase 2 small molecule completed

    1 trial

  34. NKTR-102 145 mg/m2

    Nektar Therapeutics UK Limited

    Malignant Solid Tumor

    phase 2 small molecule completed

    1 trial

  35. NKTR-102 q14d

    Nektar Therapeutics UK Limited

    Tumor

    phase 2 small molecule completed

    1 trial

  36. NKTR-181

    Nektar Therapeutics UK Limited

    Osteoarthritis of the Knee

    phase 2 small molecule completed

    1 trial

  37. NKTR-214

    Nektar Therapeutics UK Limited

    Unspecified Adult Solid Tumor, Protocol Specific

    phase 2 small molecule completed

    1 trial

  38. NKTR-214

    Nektar Therapeutics UK Limited

    Head and Neck Cancer

    phase 2 small molecule terminated

    1 trial

  39. NKTR-214

    Nektar Therapeutics UK Limited

    Non-Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  40. NKTR-255

    Nektar Therapeutics UK Limited

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  41. NKTR-255

    Nektar Therapeutics UK Limited

    Lung Cancer

    phase 2 small molecule active

    1 trial

  42. NKTR-262

    Nektar Therapeutics UK Limited

    Melanoma

    phase 2 small molecule terminated

    1 trial

  43. NKTR-358, Placebo

    Nektar Therapeutics UK Limited

    Alopecia Areata

    phase 2 small molecule active

    1 trial

  44. NKTR-358, Sodium Chloride 0.9% solution

    Nektar Therapeutics UK Limited

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  45. NMD670, Placebo

    Lacuna Pharma Pty Ltd

    Charcot-Marie-Tooth Disease Type 1 and Type 2

    phase 2 small molecule active

    1 trial

  46. NMD670-02-0001

    Lacuna Pharma Pty Ltd

    Type 3 spinal muscular atrophy

    phase 2 small molecule active

    1 trial

  47. NMD670-02-0002

    Lacuna Pharma Pty Ltd

    Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  48. NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prodromal Schizophrenia

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.